HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 04-15-2006, 04:10 AM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,783
against preconceptions: HMO patients with breast cancer had better prognosis!

Probably because they were diagnosed earlier because they did not have finances as an excuse for not getting mammogram or seeing their doctor:

1: Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):769-73. Links

The effect of medicare health care delivery systems on survival for patients with breast and colorectal cancer.

Kirsner RS, Ma F, Fleming L, Federman DG, Trapido E, Duncan R, Wilkinson JD.

Department of Dermatology, University of Miami, PO Box 016250 (R250) Miami, FL 33101. Rkirsner@med.miami.edu.

BACKGROUND: Two of the most common types of health care delivery systems in the U.S. are fee-for-service (FFS) and managed care systems such as health maintenance organizations (HMO). Differences may exist in patient outcomes depending on the health care delivery system in which they are enrolled. We evaluated differences in the survival of patients with breast and colorectal cancer at diagnosis between the two Medicare health care delivery systems (FFS and HMO). METHODS: We used a linkage of two national databases, the Medicare database from the Centers for Medicare and Medicaid Services, and the National Cancer Institute's Surveillance, Epidemiology, and End Results program database, to evaluate differences in demographic data, stage at diagnosis, and survival between breast and colorectal cancer over the period 1985 to 2001. RESULTS: Medicare patients enrolled in HMOs were diagnosed at an earlier stage of diagnosis than FFS patients. HMO patients diagnosed with breast and colorectal cancer had improved survival, and these differences remained even after controlling for potential confounders (such as stage at diagnosis, age, race, socioeconomic status, and marital status). Specifically, patients enrolled in HMOs had 9% greater survival in hazards ratio if they had breast cancer, and 6% if they had colorectal cancer. CONCLUSIONS: Differences exist in survival among patients in HMOs compared with FFS. This is likely due to a combination of factors, including but not limited to, earlier stage at the time of diagnoses. (Cancer Epidemiol Biomarkers Prev 2006;15(4):769-73).

PMID: 16614122 [PubMed - in process]
Lani is offline   Reply With Quote
Old 04-15-2006, 08:48 PM   #2
Rozebud
Senior Member
 
Rozebud's Avatar
 
Join Date: Nov 2004
Location: Olathe, KS
Posts: 107
Truly Fascinating!!
__________________
Rose

Dx'd 1/04 at 33, while 33 weeks pregnant

Dx: Stage IIIC IDC, ER-, PR+ (23%), Her2=2.7 (IDC)/7.6 (FSH), 2.5cm primary tumor, grade III, 11/18+ nodes (largest 3.8 cm)

Treatment: A/C *4, T *4, 1 year of herceptin (BCIRG 006), mastectomy, rads (7 weeks), zoladex (5 years) with tamoxifen (2 years)/aromisin (3 years), bilateral SGAP summer 05 at NOLA

Oops, retested tumor and I guess I'm er/pr- after all.
Stopped all hormonal tx 10/07. Periods resumed 6/08. Bye bye hot flashes!!!!

http://www.edrie.com/kopecky
*~VISIT OUR FAMILY!~*
Rozebud is offline   Reply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 03:19 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter